Companies › Corbus Pharmaceuticals
3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology, Metabolic and endocrine; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CRB-701 | – | Phase 3 | Oropharyngeal Carcinoma (OPC); Solid Tumor, Adult | Jan 2027 |
| CRB-601 αvβ8 integrin antagonist monoclonal antibody | ITGAV, ITGB8 | Phase 1 | Solid Tumor | Dec 2026 |
| CRB-913 | – | Phase 1 | Obese But Otherwise Healthy Participants | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07310901 | CRB-913 | Phase 1 | Obese But Otherwise Healthy Participants | Metabolic and endocrine | Aug 2026 |
| NCT06603844 | CRB-601 | Phase 1 | Solid Tumor | Oncology | Dec 2026 |
| NCT06265727 | CRB-701 | Phase 1 | Solid Tumor, Adult | Oncology | Jan 2027 |
| NCT07768189 | CRB-701 | Phase 3 | Oropharyngeal Carcinoma (OPC) | Oncology | Dec 2027 |
Cash and short-term investments of $118m on 2026-06-30; operating cash outflow about $112m a year; runway about 13 months at that burn, to Jul 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Kura Oncology Eikon Therapeutics ALX Oncology Arcus Biosciences Lyell Immunopharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.